Dal-PROTECT: prevention of organ dysfunction after high-risk abdominal surgery
Botkin Hospital · 2026 · ClinicalTrials.gov NCT07404358; updated 23 September 2026
Study findings
The phase III registry lists the randomized placebo-controlled trial as completed on 10 September 2026. No results are posted as of 11 October. The primary outcome is a seven-day composite of major postoperative complications.
- Population and setting
- 200 participants; registry reports actual enrollment
- Evidence type
- Not classified
- Source language
- English
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Completed status is not evidence of efficacy. The proposed reduction from 35% to 20% was a sample-size assumption, not an observed result.
- Registration was first posted in February 2026, after the May 2025 study start. Registry information is sponsor-reported.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Registry record
Review depth: Registry fields checked
Source access and review scope
ClinicalTrials.gov API checked: status, enrollment, intervention, outcomes and absence of results.
Recorded source-check date: 2026-10-11. This date does not imply a completed systematic review.
Source type: Clinical trial registry; results not posted
Citation and original source
Original source: Botkin Hospital. Dal-PROTECT: prevention of organ dysfunction after high-risk abdominal surgery ClinicalTrials.gov NCT07404358; updated 23 September 2026 2026.
Molekul research summary: https://molekul.io/research/dalargin-dal-protect. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry